Clinical Trial Update: A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment [Phase 3]

View source ↗

Summary

Phase 3 trial of ADS-5102 in multiple sclerosis patients with walking impairment has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• ADS-5102 (amantadine)

Snippet

Sponsor: Adamas Pharmaceuticals, Inc. | Conditions: Multiple Sclerosis, Walking Impairment | Phase 3 | Status: COMPLETED | Results posted: 2022-01-18